UCART20x22 not checked

Cellectis S.A.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen”In the company’s words, NCT05607420 on ClinicalTrials.gov
Tested for
B-cell Non-Hodgkin Lymphoma (B-NHL)
Main trialPhase 1/2
“First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).”In the company’s words, NCT05607420 on ClinicalTrials.gov

Other drugs for B-cell Non-Hodgkin Lymphoma (B-NHL)

All 166 drugs for B-cell Non-Hodgkin Lymphoma (B-NHL)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Aug 2027 Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow UCART20x22

Following is part of Solo: you see every change to UCART20x22 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in